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Effect of Paracetamol (Acetaminophen) on Body
Temperature in Acute Ischemic Stroke
A Double-Blind, Randomized Phase II Clinical Trial
D.W.J. Dippel, MD; E.J. van Breda, MD; H.M.A. van Gemert, MD; H.B. van der Worp, MD;
R.J. Meijer, MD; L.J. Kappelle, MD; P.J. Koudstaal, MD; on Behalf of the PAPAS Investigators
Background and Purpose—Body temperature is a strong predictor of outcome in acute stroke. However, it is unknown
whether antipyretic treatment leads to early and clinically worthwhile reduction of body temperature in patients with
acute stroke, especially when they have no fever. The main purpose of this trial was to study whether early treatment
of acute ischemic stroke patients with acetaminophen (paracetamol) reduces body temperature.
Methods—Seventy-five patients with acute ischemic stroke confined to the anterior circulation were randomized to
treatment with either 500 mg (low dose) or 1000 mg (high dose) acetaminophen or with placebo, administered as
suppositories 6 times daily during 5 days. Body temperatures were measured with a rectal electronic thermometer at the
start of treatment and after 24 hours and with an infrared tympanic thermometer at 2-hour intervals during the first 24
hours and at 6-hour intervals thereafter. The primary outcome measure was rectal temperature at 24 hours after the start
of treatment.
Results—Treatment with high-dose acetaminophen resulted in 0.4°C lower body temperatures than placebo treatment at
24 hours (95% CI 0.1°C to 0.7°C). The mean reduction from baseline temperature with high-dose acetaminophen was
0.3°C (95% CI 0°C to 0.6°C) higher than that in placebo-treated patients. Treatment with low-dose acetaminophen did
not result in lower body temperatures. After 5 days of treatment, no differences in temperature were found between the
placebo and the high- or low-dose acetaminophen groups.
Conclusions—Treatment with a daily dose of 6000 mg acetaminophen may result in a small, but potentially beneficial,
decrease in body temperature shortly after ischemic stroke, even in normothermic and subfebrile patients. Further
studies should determine whether this effect is reproducible and whether early reduction of body temperature leads to
improved outcome. (Stroke. 2001;32:1607-1612.)
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During the first days after acute stroke, a fever orsubfebrile temperature develops in one fifth to almost
one half of patients.1–4 Increased temperature may have a
detrimental effect on the outcome after ischemic stroke.
Subfebrile temperatures (37.5°C to 39°C) and fever (.39°C)
after a stroke are associated with relatively large infarct
volumes, high case fatality, and poor functional outcome,
even after adjustment for initial stroke severity.2–6 The period
in which hyperthermia is associated with poor outcome may
be limited to the first 12 or 24 hours from stroke onset.6,7
The harmful effects of an early rise in body temperature
have been attributed to increased cerebral metabolic de-
mands,8 changes in the blood-brain barrier permeability,
acidosis, and an increased release of excitatory amino acids.9
In animal models of temporary focal cerebral ischemia, mild
intraischemic hyperthermia increased infarct volume,10
whereas mild hypothermia reduced infarct size.11
A pharmacological reduction of body temperature in pa-
tients with acute ischemic stroke may improve functional
outcome. To date, however, there are no controlled studies of
the effects of antipyretic agents on temperature in these
patients or of the effect of temperature reduction on outcome.
Moreover, the effect of antipyretic agents on body core
temperature in stroke patients with a normal temperature at
the onset has not been investigated.
Acetaminophen (paracetamol) has a weak inhibitory effect
on peripheral prostaglandin biosynthesis (which accounts for
its weak anti-inflammatory activity), but it is a potent inhib-
itor of prostaglandin production within the central nervous
system. This presumably accounts for its analgesic and
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antipyretic properties.12 Acetaminophen is usually well toler-
ated, has almost no side effects or drug interactions at
therapeutic doses, and has no effect on cardiovascular and
respiratory systems.12 Its use in stroke patients to treat and
prevent fever has been advocated, but the effectiveness of
such a treatment has never been studied.13,14
There are several arguments against routinely prescribing
acetaminophen for patients with stroke. First, there is a safety
concern, because treatment with acetaminophen may mask
fever, which may lead to later detection of pneumonia, urinary
tract infections, and sepsis. Moreover, large doses of acetamin-
ophen may lead to acute liver failure, especially in patients with
chronic liver disease. Second, it has not been established
whether active reduction of body temperature in patients with
acute stroke will lead to an improved clinical outcome.15 Third,
it is equally unknown whether treatment with acetaminophen
leads to early and clinically worthwhile reduction of body
temperature in stroke patients, especially when they have no
initial fever or subfebrile temperature. Therefore, the main
purpose of this study was to determine whether early treatment
in the acute stage leads to a lower body temperature than when
there is no treatment.
Methods
Setting
Paracetamol (Acetaminophen) in Patients with Acute Stroke
(PAPAS) was a 3-center, randomized, double-blind, placebo-
controlled, parallel-group study of high- and medium-dose acetamin-
ophen in patients with acute ischemic stroke. The study was carried
out in 3 hospitals: 2 university hospitals with a regional patient care
function, and 1 large regional hospital.
Patients
Patients with a clinical diagnosis of acute ischemic anterior circula-
tion stroke were included in the study. A cranial CT scan was
obligatory before randomization and had to be compatible with acute
ischemic stroke. All patients were required to have a stable focal
deficit without rapid improvement and the possibility of starting
treatment within 24 hours to be included in the study.
Patients were excluded if their body temperature at admission was
,36.0°C or .39.0°C or if they had already been treated with steroids or
nonsteroidal ant-inflammatory drugs within 3 days before the stroke,
because this could confound a possible treatment effect. We also
excluded patients with a severe illness of a different nature, which could
affect the assessment of the effect of the study medication on temper-
ature, and patients with residual neurological impairment resulting from
a previous stroke, which could influence the assessment of functional
outcome.
Because of safety considerations, we excluded patients with chronic
liver failure or cirrhosis, chronic renal failure, or a history of alcohol
abuse and those who were allergic to acetaminophen or aspirin.
Furthermore, patients who were moribund and those for whom no
informed consent was given were not included in the study.
Ethical Aspects
All patients were given verbal and written information about the
potential risks and benefits of participation in the study. Written
consent was required before randomization. The medical ethics
committee of each participating center approved the study protocol.
Treatment Allocation and Blinding
Treatment consisted of suppositories containing 500 mg (low dose)
acetaminophen, 1000 mg (high dose) acetaminophen, or placebo,
given 6 times daily for 5 days. We used suppositories because we
anticipated a high incidence of swallowing difficulties early after
stroke. The study medication was provided in white paper boxes,
numbered consecutively with a medication number. The treatment
allocation schedule was based on computer-generated random num-
bers. The treatment codes resided with the hospital pharmacist in
each center. One copy of the treatment codes was kept by the
secretary (A.K.) of the Safety Monitoring Committee, whose mem-
bers were not involved in execution of the study. The Executive
Committee and the local investigators were not aware of treatment
assignments. No treatment code was broken before the last follow-up
visit was completed. The treatment allocation was stratified for early
(within 12 hours) and late (12 to 24 hours) treatment, and the study
medication was blocked in lots of 6 (each by center).
Study Activities
All patients were admitted to an acute stroke care unit. The National
Institutes of Health Stroke Scale (NIHSS) was used to assess the
severity of the stroke.16 After 1 month, stroke type was classified
according to the TOAST criteria.17 Body temperature was measured
by means of a standard rectal electronic thermometer at the start of
treatment and 24 hours later. Tympanic temperatures were taken at
2-hour intervals during the first day and at 6-hour intervals during the
next 6 days. Because the acetaminophen dose in the high-dose group
exceeded the usually recommended maximal dosage of 4 g/d, we
assessed potential effects on liver enzymes at baseline and after 5
days.
Outcome Measures
The primary outcome measure in this study was body temperature at 24
hours from the start of treatment, measured with a rectal thermometer.
Secondary outcome measures were reduction in body temperature after
1 and 5 days from the start of treatment and the area under the 1- and
5-day temperature curves. As a tertiary outcome measure, we deter-
Figure 1. Treatment allocation and participant flow. The number
of patients who completed assessment at 4 weeks could be
larger than the number who completed the 5-day treatment
period, because some patients were discharged early and dis-
continued the study medication.
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mined stroke severity at 1 month, as defined by the score on the
modified Rankin scale,18 although this study was not designed to detect
a significant effect on clinical outcome.
Safety
Serious adverse events were defined as any potentially life-
threatening deterioration in health status within the study monitoring
period (day 0 to day 7). Adverse events included any infection, such
as pneumonia, sepsis, or urinary tract infection that requires antibi-
otic treatment according to the judgment of the treating physician;
any liver function disturbance (ASAT, ALAT, AF, or total bilirubin
levels that exceed twice the local upper limit of normal); and any
neurological deterioration (ie, decrease in level of consciousness of
.1 point on the Glasgow Coma Scale or an increase of $2 points on
the NIHSS). Then independent, unblinded Safety and Data Monitor-
ing Committee reviewed all serious adverse events on a weekly
basis.
Statistical Analysis
The study results were analyzed on an intention-to-treat basis. No
interim analysis was carried out. The main results of the study are
presented as the mean absolute difference in temperature between the
2 treatment groups and the control group, with 95% CIs. Multiple
linear regression was performed to study a possible dose-effect
relationship between treatment and body temperature and to adjust
for possible confounding factors, such as age, ischemic stroke
subtype, stroke severity, and body temperature at admission and at
the start of treatment.
Sample Size
It was determined beforehand that a 0.5°C difference in body temper-
ature after 24 hours would be clinically significant. Such a difference
could be equivalent to a 5% to 10% absolute lower risk of poor outcome
in patients with a moderately severe stroke.6 To be able to detect a
difference in body temperature at 24 hours of 0.5°C, with a significance
level of 0.05 and power of 0.80, assuming an SD of 0.6°C, we would
need $23 patients in each treatment group. This number was rounded to
25. No formal statistical stopping rule was used.
Results
Participant Flow and Follow-Up
Seventy-six patients were randomized and included in the
study. Twenty-six patients were allocated to treatment with
high-dose acetaminophen, 25 to medium-dose acetamino-
phen, and 25 to placebo.
One patient, who awoke with a right-sided hemiparesis and
aphasia, was diagnosed as having a low-grade glioma, 2 days
after inclusion in the study. This patient was excluded from
the analysis. Another patient, a 51-year-old man with a pure
sensory stroke, was lost to follow-up after having been
Figure 2. Mean body temperatures during the first 24 hours
after the start of treatment according to treatment.
TABLE 1. Baseline Characteristics
High Dose
(n526)
Medium Dose
(n525)
Placebo
(n524)
Demographics
Age, y, mean (SD) 69 (13) 74 (14) 68 (15)
Male sex, n (%) 12 (46) 14 (56) 16 (67)
Risk factor for stroke, n (%)
Hypertension 12 (46) 12 (48) 13 (54)
Cardiac disease 10 (38) 9 (36) 6 (25)
Peripheral vascular disease 3 (12) 2 (8) 2 (8)
Diabetes mellitus 4 (15) 4 (16) 3 (13)
Hypercholesterolemia 6 (23) 5 (20) 8 (33)
Previous transient ischemic attack 5 (19) 5 (20) 5 (21)
Previous stroke 4 (15) 3 (12) 4 (17)
Cigarette smoking 10 (42) 12 (48) 17 (71)
Neurological characteristic, n (%)
Lowered consciousness level 6 (23) 6 (24) 3 (13)
Aphasia, n (%) 5 (19) 11 (44) 7 (29)
NIHSS, mean (SD) 8.8 (5.6) 10.0 (8.2) 6.8 (5.4)
Lacunar stroke, n (%) 10 (38) 5 (20) 11 (46)
Other clinical characteristic
Treatment within 0–12 h, n (%) 11 (42) 11 (44) 11 (44)
Temperature at admission, mean °C (SD) 36.9 (0.65) 36.9 (0.76) 36.9 (0.64)
Temperature at start of treatment, mean °C (SD) 37.1 (0.47) 37.2 (0.41) 37.2 (0.51)
Medium dose indicates 500 mg acetaminophen 6 times daily; high dose, 1000 mg, 6 times daily.
Values are absolute numbers with percentages of totals in treatment strata, unless stated otherwise.
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discharged 6 days after the onset of symptoms (Figure 1). In
this patient, the last observation of functional outcome was
carried forward. Both these patients were receiving placebo.
Nine patients discontinued the study medication because they
were discharged early after a speedy recovery; these patients
did complete the 1-month follow-up assessment. Six patients
died after the treatment was completed but before the sched-
uled 1-month follow-up.
No crossovers occurred, and all patients were treated accord-
ing to the allocated protocol at least during the first 24 hours,
until the primary outcome assessment. For all patients in the
study, the blinding was maintained, and no applications for
unblinding were made by the local investigators. No safety
concerns were raised by the Data Monitoring and Safety
Committee.
The clinical characteristics of the study population are sum-
marized in Table 1. The treatment groups were balanced with
regard to potential determinants of body temperature, except for
a slight excess of patients with nonlacunar infarction and with
aphasia in the medium-dose group. The score on the NIHSS was
on average 3.2 points higher in the medium-dose group than in
the placebo group and 2.0 points higher in the high-dose group
than in the placebo group, suggesting more severe strokes in the
patients receiving active treatment.
Main Results
The mean body temperature at 24 hours after the start of
treatment was 0.4°C lower in the high-dose group than in the
placebo group (95% CI 0.1°C to 0.7°C) (Figure 2 and Table 2).
The mean reduction in body temperature during the first 24
hours of treatment differed by 0.3°C between the high-dose and
placebo groups (95% CI 0°C to 0.6°C). The area under the curve
was significantly smaller in the high-dose group, at least during
the first 24 hours of treatment, which implies that the total time
with elevated temperature in that period decreased with the use
of acetaminophen. Adjustment for stroke severity (NIHSS at
baseline), stroke type (lacunar or nonlacunar), or start of treat-
ment (within 12 hours or between 12 to 24 hours) by multiple
linear regression did not change the effect estimate of 0.4°C in
the high-dose treatment group.
On day 5, no statistically significant difference in body
temperature was observed between the placebo and medium- or
high-dose group (Table 2).
In an “on-treatment” analysis, we excluded data from patients
who did not actually take their study medication. This did not
change the effect estimates; most likely because all patients
completed the 24-hour treatment period and 67 (89%) completed
the 5-day treatment period.
Functional outcome at 1 month did not differ significantly
among the 3 treatment groups. Twelve patients in the placebo
group (48%), 13 (52%) in the medium-dose group, and 17
(65%) in the high-dose group had a poor outcome (modified
Rankin scale .2). The relative risk (OR) of poor outcome due to
high-dose acetaminophen compared with placebo was 1.9 (95%
CI 0.6 to 5.9), but after adjustment for baseline NIHSS in a
multiple logistic regression model, this relative risk was reduced
to 1.1 (95% CI 0.2 to 5.7). Thus, an apparent adverse effect of
high-dose acetaminophen on functional outcome could be attrib-
uted to a slight imbalance in the distribution of stroke severity at
baseline in this study.
Serious Adverse Events
Six patients died during the study: 1 from pneumonia leading
to sepsis, 2 from myocardial infarction, and 3 from progres-
sive stroke. The patient with pneumonia had been allocated to
the placebo group. Serious adverse events did not occur more
often in the patients on active treatment than in the patients
receiving placebo (Table 3).
Discussion
After 24 hours of treatment, we found a small, but statistically
significant, difference in body temperature in favor of treat-
ment with high-dose acetaminophen. A difference of 0.4°C
may not seem impressive. However, keeping in mind the
results of the Copenhagen Stroke Study, which suggested a
2-fold increase in mortality risk for every 1°C increase in
body temperature and an average 3.9-point increase in Scan-
dinavian Stroke Score,6 this effect on temperature may be
worthwhile, given the low cost and safety of acetaminophen.
These results should also provide a stimulus to continue the
search for a more effective medical regimen for decreasing
body temperature and, perhaps, improving outcome after
acute ischemic stroke.
TABLE 2. Average Body Temperatures at 24 Hours and 5 Days After Start of Treatment and
Area Under the Curve for High-Dose, Medium-Dose, and Placebo Groups
High Dose Medium Dose Placebo
High Dose Minus
Placebo (95% CI)
Temperature at 24 h, °C (SD) 37.0 (0.37) 37.5 (0.47) 37.4 (0.64) 20.4 (20.7 to 20.1)
Reduction in temperature at 24 h, °C (SD) 0.1 (0.5) 20.2 (0.5) 20.2 (0.6) 0.3 (0 to 0.6)
Reduction in temperature at 5 d, °C (SD) 0.2 (0.5) 0.1 (0.5) 0.2 (0.5) 0 (20. to 0.3)
AUC first treatment day, °C3h (SD) 886 (13) 891 (10) 894 (15) 28 (217 to 0)
AUC total treatment period, °C3h (SD) 4423 (52) 4445 (56) 4454 (64) 231 (267 to 5)
TABLE 3. Serious Adverse Events
Serious Adverse Events, n (%) High Dose Medium Dose Placebo
Pneumonia/sepsis 3 (12) 4 (16) 1 (4)
Neurological deterioration 0 (0) 1 (4) 3 (13)
Liver function disturbance* 6 (23) 6 (24) 8 (33)
Death 1 (4) 4 (16) 1 (4)
Other 0 (0) 2 (8) 0 (0)
*AF, ALAT, or bilirubin 23 upper limit of normal.
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The concern that treatment with an antipyretic drug may mask
emerging infections, and thus lead to treatment delay, sepsis, and
poor outcome, was not substantiated in this study.
We measured body temperature with a standard rectal ther-
mometer. The relationship between body temperature (measured
with a rectal thermometer) and brain temperature is controver-
sial.19 The results of the Copenhagen Stroke Study, in which
only rectal temperature was measured, should have made this
discussion unnecessary.6 Moreover, in a study of moderate
hypothermia in patients with traumatic brain injury, rectal
temperatures remained very close to actual brain temperatures,
as measured intracranially.20
We did not measure plasma concentrations of acetaminophen
in this study. Such information would have been helpful in
explaining the lack of effect in the medium-dose group, in
further exploring a dose-response relationship, and in designing
further pragmatic studies that make use of oral acetaminophen.
One may argue that increased body temperature does not
accelerate the ischemic cascade but is merely an epiphenome-
non. In the Copenhagen study, however, the relationship be-
tween body temperature and outcome remained statistically
significant after adjustment for initial stroke severity.6 This
makes it less likely that body temperature only reflects the
amount of brain tissue damage. Early body temperature mea-
surements (within the first 6 hours) seem to be more strongly
related to outcome than later measurements. This suggests that
the relationship with poor outcome is not confounded by the
occurrence of secondary infections, such as pneumonia or
urinary tract infection, because these usually appear later in the
course of the disease. Moreover, animal studies of acute middle
cerebral artery territory ischemia suggest a protective effect of
early hypothermia and a detrimental effect of induced hyperther-
mia.10 In a recent study of 725 consecutive patients admitted
within 6 hours from the onset of acute ischemic stroke, no
relation was found between initial body temperature and out-
come.18 The authors did use a rather insensitive method of
statistical analysis (Spearman correlation and comparison of
median modified Rankin scale scores with a nonparametric test).
All patients with a body temperature of .37.0°C were treated
with acetaminophen. Consequently, the results of this study
should be interpreted with care.
To the best of our knowledge, no other randomized, con-
trolled study of medical treatment that aimed at decreasing body
or brain temperature in patients with ischemic stroke has been
published. In a randomized clinical trial of moderate hypother-
mia (633°C) in patients with severe head injury, a beneficial
effect on speed of recovery and on the rate of good outcome was
noted in the subgroup with a Glasgow Coma Scale score of 5 to
7,20 although in a more recent and larger study, no effect of
moderate hypothermia was found.21
The induction of moderate hypothermia was studied in a
small study of patients with severe ischemic stroke in the
territory of the middle cerebral artery. Temperatures of 34°C
were reached, but a drawback of this approach was that patients
had to be heavily sedated and artificially ventilated.22 Recently,
Kammersgaard et al23 reported that hypothermic therapy with a
forced air method for a period of 6 hours in unanesthetized
stroke patients was sufficient to lower body temperature by
1.3°C on average. This procedure was well tolerated, but
intravenous meperidine (pethidine) had to be used to control
shivering. A similar approach with low-dose midazolam to
control shivering resulting in a mean reduction of 1.25°C was
used by our group.24 An important drawback of mechanical
cooling is the need for some kind of analgesia and sedation, as
well as the necessity of constant monitoring.
Conclusions
Treatment with high-dose acetaminophen results in a small,
but potentially worthwhile, decrease in body temperature
early in the acute phase of stroke, even in normothermic
patients. Further studies should determine whether this effect
of acetaminophen can be reproduced and whether an early
reduction in body temperature leads to improved outcome.
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